Search

Your search keyword '"Newsome, Simon"' showing total 131 results

Search Constraints

Start Over You searched for: Author "Newsome, Simon" Remove constraint Author: "Newsome, Simon"
131 results on '"Newsome, Simon"'

Search Results

1. Prognostic Significance of Nonischemic Myocardial Fibrosis in Patients With Normal LV Volumes and Ejection-Fraction

2. End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?

4. Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation

5. Microvascular Dysfunction in Dilated Cardiomyopathy: A Quantitative Stress Perfusion Cardiovascular Magnetic Resonance Study

7. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial

8. Absence of Myocardial Fibrosis Predicts Favorable Long-Term Survival in New-Onset Heart Failure: A Cardiovascular Magnetic Resonance Study

11. Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional Data

12. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

13. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

14. Prognostic significance of nonischaemic myocardial fibrosis in patients with normal left ventricular volumes and ejection-fraction

15. Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

17. Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

18. Abstract CT162: The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)

19. Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).

20. Predictors of left ventricular remodelling in patients with dilated cardiomyopathy – a cardiovascular magnetic resonance study

21. Using Negative Control Outcomes and Difference-in-Differences Analysis to Estimate Treatment Effects in an Entirely Treated Cohort: The Effect of Ivacaftor in Cystic Fibrosis.

23. Sex‐ and age‐based differences in the natural history and outcome of dilated cardiomyopathy

24. Absence of Myocardial Fibrosis Predicts Favorable Long-Term Survival in New-Onset Heart Failure

25. Outcome in dilated cardiomyopathy related to the extent, location and pattern of late gadolinium enhancement

26. Estimating long-term treatment effects in observational data: A comparison of the performance of different methods under real-world uncertainty

27. Phenotype and Clinical Outcomes of Titin Cardiomyopathy

29. Sex‐ and age‐based differences in the natural history and outcome of dilated cardiomyopathy

30. D Perfusion abnormalities in hypertrophic cardiomyopathy: mechanisms and prognostic importance

32. DEFINING THE RELATIONSHIP BETWEEN THE EXTENT OF MID-WALL LATE GADOLINIUM ENHANCEMENT AND ADVERSE HEART FAILURE EVENTS IN PATIENTS WITH DILATED CARDIOMYOPATHY

33. PROGNOSTIC SIGNIFICANCE OF NON-ISCHAEMIC MYOCARDIAL FIBROSIS IN PATIENTS WITH NORMAL LV SIZE AND FUNCTION: A LARGE CMR REGISTRY STUDY

34. SEX DIFFERENCES IN THE NATURAL HISTORY AND OUTCOME OF DILATED CARDIOMYOPATHY

35. Data Resource Profile:The UK Cystic Fibrosis Registry

37. Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance

38. 127 Relationship between plasma concentrations of b-type natriuretic peptide and exercise capacity in hypertrophic cardiomyopathy

40. Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction

42. 002 Sudden cardiac death risk stratification in patients with mild dilated cardiomyopathy

47. Predicting two-year mortality from discharge after acute coronary syndrome: An internationally-based risk score

48. Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry

Catalog

Books, media, physical & digital resources